| It is estimated that about 50% of drugs in development fail during clinical trials because of deficiencies in their ADME/Tox properties (absorption, distribution, metabolism, elimination and toxicity). The cost of these failures so late in the drug development process is naturally very high. In addition, it has been suggested that over 5% of hospitalized patients suffer serious adverse reactions to drugs that have successfully completed their development and come onto the market. Improved means of gathering ADME/Tox information earlier in the drug development process should thus benefit both pharmaceutical manufacturers and, of course, patients.
To understand the processes related to the metabolism and potential toxicity of a candidate drug we chose to combine the method of 2-D Difference Gel Electrophoresis (DIGE) to highlight proteins which are significantly up- or down-regulated after the administration of the drug, with mass spectrometric analysis to unambiguously identify such proteins.
To read the complete application note, please download the PDF file on this page.
You can now also order additional proteomics resources, or learn about other mass spectrometry or proteomics solutions. |
0 Items 